Plaintiffs continue to file new lawsuits against AbbVie. Inc and Abbott Laboratories, Inc. They allege that their Testosterone Replacement Therapy (TRT) drug, called AndroGel causes significant damages, including heart attacks.
Plaintiffs from anywhere in the U.S. may file their claims into the consolidated multidistrict litigation (MDL) in the Northern District of Illinois. There are now more than 2,000 lawsuits filed in the testosterone MDL and many more are expected to join over the next few months.
The latest complaint was brought by on behalf of a man who had been prescribed AndroGel for the treatment of symptoms that he had attributed to low testosterone after having seen the defendants’ advertisements for AndroGel.
The lawsuit brings charges AbbVie Inc. and Abbott Laboratories, Inc. with a failure to warn the public about significant risks that the companies had known about or should have known about. This most recent case alleges that the defendants had misrepresented AndroGel’s safety and effectiveness, and that defendants did so intentionally to increase sales.